GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators

LA JOLLA, CA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that European Patent Office (EPO) has issued a decision to grant notice for patent application number 19,166,502 titled, “Oxygenated Amino- or Ammonium-Containing Sulfonic Acid, Phosphonic Acid and Carboxylic Acid Derivatives and Their Medical Use.” Based on the intention to grant notice, the Company expects the EPO to issue a patent January 16, 2025.

Read more at globenewswire.com